{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:48:38Z","timestamp":1759340918847},"reference-count":119,"publisher":"Bentham Science Publishers Ltd.","issue":"17","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2019,9,19]]},"abstract":"<jats:sec>\n<jats:title \/>\n<jats:p>Retinoblastoma is the intraocular malignancy that occurs during early childhood. The current\nstandard of care includes chemotherapy followed by focal consolidative therapies, and enucleation. Unfortunately,\nthese are associated with many side and late effects. New drugs and\/or drug combinations\nneed to be developed for safe and effective treatment. This compelling need stimulated efforts to explore\ndrug repurposing for retinoblastoma. While conventional drug development is a lengthy and expensive\nprocess, drug repurposing is a faster, alternate approach, where an existing drug, not meant for treating\ncancer, can be repurposed to treat retinoblastoma. The present article reviews various attempts to test\ndrugs approved for different purposes such as calcium channels blockers, non-steroidal antiinflammatory\ndrugs, cardenolides, antidiabetic, antibiotics and antimalarial for treating retinoblastoma.\nIt also discusses other promising candidates that could be explored for repurposing for retinoblastoma.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026619666190119152706","type":"journal-article","created":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T14:34:43Z","timestamp":1547908483000},"page":"1535-1544","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Drug Repurposing for Retinoblastoma: Recent Advances"],"prefix":"10.2174","volume":"19","author":[{"given":"Kamakshi","family":"Dandu","sequence":"first","affiliation":[{"name":"CSIR-Centre for Cellular and Molecular Biology, Uppal Road, Habsiguda, Hyderabad 500 007, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prathap R.","family":"Kallamadi","sequence":"additional","affiliation":[{"name":"School of Life Sciences. University of Hyderabad, Prof. C.R. Rao Road, Hyderabad 500 046, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman S.","family":"Thakur","sequence":"additional","affiliation":[{"name":"CSIR-Centre for Cellular and Molecular Biology, Uppal Road, Habsiguda, Hyderabad 500 007, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ch. Mohan","family":"Rao","sequence":"additional","affiliation":[{"name":"CSIR-Centre for Cellular and Molecular Biology, Uppal Road, Habsiguda, Hyderabad 500 007, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1615\/CritRevOncog.2015013711","volume":"20","author":"McEvoy J.D.","year":"2015","unstructured":"McEvoy J.D.; Dyer M.A.; Genetic and epigenetic discoveries in human retinoblastoma. Crit Rev Oncog 2015,20(3-4),217-225","journal-title":"Crit Rev Oncog"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/01.icu.0000193079.55240.18","volume":"17","author":"Shields C.L.","year":"2006","unstructured":"Shields C.L.; Shields J.A.; Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol 2006,17(3),228-234","journal-title":"Curr Opin Ophthalmol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1038\/sj.onc.1209622","volume":"25","author":"Balmer A.","year":"2006","unstructured":"Balmer A.; Zografos L.; Munier F.; Diagnosis and current management of retinoblastoma. Oncogene 2006,25(38),5341-5349","journal-title":"Oncogene"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.12688\/f1000research.11941.1","volume":"7","author":"Schefler A.C.","year":"2018","unstructured":"Schefler A.C.; Kim R.S.; Recent advancements in the management of retinoblastoma and uveal melanoma. F1000 Res 2018,7,476","journal-title":"F1000 Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s11060-012-0922-4","volume":"109","author":"Rodjan F.","year":"2012","unstructured":"Rodjan F.; de Graaf P.; Brisse H.J.; G\u00f6ricke S.; Maeder P.; Galluzzi P.; Aerts I.; Alapetite C.; Desjardins L.; Wieland R.; Popovic M.B.; Diezi M.; Munier F.L.; Hadjistilianou T.; Knol D.L.; Moll A.C.; Castelijns J.A.; Trilateral retinoblastoma: neuroimaging characteristics and value of routine brain screening on admission. J Neurooncol 2012,109(3),535-544","journal-title":"J Neurooncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/pbc.20793","volume":"48","author":"Antoneli C.B.","year":"2007","unstructured":"Antoneli C.B.; Ribeiro, Kde.C.; Sakamoto, L.H.; Chojniak, M.M.; Novaes, P.E.; Arias, V.E. Trilateral retinoblastoma. Pediatr Blood Cancer 2007,48(3),306-310","journal-title":"Pediatr Blood Cancer"},{"key":"ref=7","first-page":"951","volume":"42","author":"Shields J.A.","year":"1990","unstructured":"Shields J.A.; Shields C.L.; Treatment of retinoblastoma with photocoagulation. Trans Pa Acad Ophthalmol Otolaryngol 1990,42,951-954","journal-title":"Trans Pa Acad Ophthalmol Otolaryngol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/archopht.117.7.885","volume":"117","author":"Shields C.L.","year":"1999","unstructured":"Shields C.L.; Santos M.C.; Diniz W.; G\u00fcnd\u00fcz K.; Mercado G.; Cater J.R.; Shields J.A.; Thermotherapy for retinoblastoma. Arch Ophthalmol 1999,117(7),885-893","journal-title":"Arch Ophthalmol"},{"key":"ref=9","first-page":"977","volume":"42","author":"Shields J.A.","year":"1990","unstructured":"Shields J.A.; Shields C.L.; Treatment of retinoblastoma with cryotherapy. Trans Pa Acad Ophthalmol Otolaryngol 1990,42,977-980","journal-title":"Trans Pa Acad Ophthalmol Otolaryngol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5497\/wjp.v2.i3.65","volume":"9","author":"Shah N.V.","year":"2013","unstructured":"Shah N.V.; Houston S.K.; Murray T.G.; Retinoblastoma and treatment: A current evaluation of advanced therapy. World J Pharmacol 2013,9,65-72","journal-title":"World J Pharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0161-6420(93)31667-2","volume":"100","author":"Shields C.L.","year":"1993","unstructured":"Shields C.L.; Shields J.A.; De Potter P.; Minelli S.; Hernandez C.; Brady L.W.; Cater J.R.; Plaque radiotherapy in the management of retinoblastoma. Use as a primary and secondary treatment. Ophthalmology 1993,100(2),216-224","journal-title":"Ophthalmology"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1001\/archopht.117.6.766","volume":"117","author":"Scott I.U.","year":"1999","unstructured":"Scott I.U.; Murray T.G.; Feuer W.J.; Van Quill K.; Markoe A.M.; Ling S.; Roth D.B.; O\u2019Brien J.M.; External beam radiotherapy in retinoblastoma: tumor control and comparison of 2 techniques. Arch Ophthalmol 1999,117(6),766-770","journal-title":"Arch Ophthalmol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1442-9071.2007.01602.x","volume":"36","author":"Munier F.L.","year":"2008","unstructured":"Munier F.L.; Verwey J.; Pica A.; Balmer A.; Zografos L.; Abouzeid H.; Timmerman B.; Goitein G.; Moeckli R.; New developments in external beam radiotherapy for retinoblastoma: from lens to normal tissue-sparing techniques. Clin Exp Ophthalmol 2008,36(1),78-89","journal-title":"Clin Exp Ophthalmol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/ICU.0b013e328338676a","volume":"21","author":"Shields C.L.","year":"2010","unstructured":"Shields C.L.; Shields J.A.; Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol 2010,21(3),203-212","journal-title":"Curr Opin Ophthalmol"},{"key":"ref=15","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19467-7_7","author":"Bhinder B.","year":"2015","unstructured":"Bhinder B.; Mahida J.P.; Ib\u00e1\u00f1ez G.; Champ K.; Antczak C.; Djaballah H.;  Drug Discovery and Repurposing for Retinoblastoma Recent Ad-vances in Retinoblastoma Treatment Essentials in Ophthal-mology; Francis J; 2015","journal-title":"Drug Discovery and Repurposing for Retinoblastoma Recent Ad-vances in Retinoblastoma Treatment Essentials in Ophthal-mology; Francis J;"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"430","DOI":"10.2174\/1389557515666150722100610","volume":"16","author":"Pritchard E.M.","year":"2016","unstructured":"Pritchard E.M.; Dyer M.A.; Guy R.K.; Progress in small molecule therapeutics for the treatment of retinoblastoma. Mini Rev Med Chem 2016,16(6),430-454","journal-title":"Mini Rev Med Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4274\/tjo.06888","volume":"45","author":"Yan\u0131k \u00d6.","year":"2015","unstructured":"Yan\u0131k \u00d6.; G\u00fcnd\u00fcz K.; Yavuz K.; Ta\u00e7y\u0131ld\u0131z N.; \u00dcnal E.; Chemotherapy in retinoblastoma: Current approaches. Turk J Ophthalmol 2015,45(6),259-267","journal-title":"Turk J Ophthalmol"},{"key":"ref=18","first-page":"151","volume":"23","author":"Macdonald M.R.","year":"1994","unstructured":"Macdonald M.R.; Harrison R.V.; Wake M.; Bliss B.; Macdonald R.E.; Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngol 1994,23(3),151-159","journal-title":"J Otolaryngol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/archopht.121.8.1120","volume":"121","author":"Mulvihill A.","year":"2003","unstructured":"Mulvihill A.; Budning A.; Jay V.; Vandenhoven C.; Heon E.; Gallie B.L.; Chan H.S.; Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol 2003,121(8),1120-1124","journal-title":"Arch Ophthalmol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ajo.2006.02.044","volume":"142","author":"Schmack I.","year":"2006","unstructured":"Schmack I.; Hubbard G.B.; Kang S.J.; Aaberg T.M.; Grossniklaus H.E.; Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol 2006,142(2),310-315","journal-title":"Am J Ophthalmol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cncr.23988","volume":"115","author":"Hijiya N.","year":"2009","unstructured":"Hijiya N.; Ness K.K.; Ribeiro R.C.; Hudson M.M.; Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer 2009,115(1),23-35","journal-title":"Cancer"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.bbamcr.2015.11.032","volume":"1863","author":"Leanza L.","year":"2016","unstructured":"Leanza L.; Manag\u00f2 A.; Zoratti M.; Gulbins E.; Szabo I.; Pharmacological targeting of ion channels for cancer therapy: In vivo evidences. Biochim Biophys Acta 2016,1863(6 Pt B),1385-1397","journal-title":"Biochim Biophys Acta"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00424-013-1427-5","volume":"466","author":"Zhang Y.","year":"2014","unstructured":"Zhang Y.; Wang H.; Qian Z.; Feng B.; Zhao X.; Jiang X.; Tao J.; Low-voltage-activated T-type Ca2+ channel inhibitors as new tools in the treatment of glioblastoma: the role of endostatin. Pflugers Arch 2014,466(4),811-818","journal-title":"Pflugers Arch"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.apsb.2016.11.001","volume":"7","author":"Cui C.","year":"2017","unstructured":"Cui C.; Merritt R.; Fu L.; Pan Z.; Targeting calcium signaling in cancer therapy. Acta Pharm Sin B 2017,7(1),3-17","journal-title":"Acta Pharm Sin B"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1016\/j.bbamem.2015.03.034","volume":"1848","author":"Kale V.P.","year":"2015","unstructured":"Kale V.P.; Amin S.G.; Pandey M.K.; Targeting ion channels for cancer therapy by repurposing the approved drugs. Biochim Biophys Acta 2015,1848(10 Pt B),2747-2755","journal-title":"Biochim Biophys Acta"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ceca.2006.04.017","volume":"40","author":"Lory P.","year":"2006","unstructured":"Lory P.; Bidaud I.; Chemin J.; T-type calcium channels in differentiation and proliferation. Cell Calcium 2006,40(2),135-146","journal-title":"Cell Calcium"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ceca.2006.04.029","volume":"40","author":"Panner A.","year":"2006","unstructured":"Panner A.; Wurster R.D.; T-type calcium channels and tumor proliferation. Cell Calcium 2006,40(2),253-259","journal-title":"Cell Calcium"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00424-014-1444-z","volume":"466","author":"Dziegielewska B.","year":"2014","unstructured":"Dziegielewska B.; Gray L.S.; Dziegielewski J.; T-type calcium channels blockers as new tools in cancer therapies. Pflugers Arch 2014,466(4),801-810","journal-title":"Pflugers Arch"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/S0735-1097(99)00447-7","volume":"34","author":"Mason R.P.","year":"1999","unstructured":"Mason R.P.; Calcium channel blockers, apoptosis and cancer: is there a biologic relationship? J Am Coll Cardiol 1999,34(7),1857-1866","journal-title":"J Am Coll Cardiol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0006-8993(92)90162-3","volume":"598","author":"Barnes S.","year":"1992","unstructured":"Barnes S.; Haynes L.W.; Low-voltage-activated calcium channels in human retinoblastoma cells. Brain Res 1992,598(1-2),19-22","journal-title":"Brain Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1152\/jn.2002.88.1.196","volume":"88","author":"Hirooka K.","year":"2002","unstructured":"Hirooka K.; Bertolesi G.E.; Kelly M.E.; Denovan-Wright E.M.; Sun X.; Hamid J.; Zamponi G.W.; Juhasz A.E.; Haynes L.W.; Barnes S.; T-Type calcium channel alpha1G and alpha1H subunits in human retinoblastoma cells and their loss after differentiation. J Neurophysiol 2002,88(1),196-205","journal-title":"J Neurophysiol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1124\/mol.62.2.210","volume":"62","author":"Bertolesi G.E.","year":"2002","unstructured":"Bertolesi G.E.; Shi C.; Elbaum L.; Jollimore C.; Rozenberg G.; Barnes S.; Kelly M.E.; The Ca(2+) channel antagonists mibefradil and pimozide inhibit cell growth via different cytotoxic mechanisms. Mol Pharmacol 2002,62(2),210-219","journal-title":"Mol Pharmacol"},{"key":"ref=33","first-page":"425","volume":"83","author":"Bozimowski G.","year":"2015","unstructured":"Bozimowski G.; A review of nonsteroidal anti-inflammatory drugs. AANA J 2015,83(6),425-433","journal-title":"AANA J"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003495-199600525-00004","volume":"52","author":"Cashman J.N.","year":"1996","unstructured":"Cashman J.N.; The mechanisms of action of NSAIDs in analgesia. Drugs 1996,52(5)(Suppl. 5),13-23","journal-title":"Drugs"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","volume":"38","author":"Vane J.R.","year":"1998","unstructured":"Vane J.R.; Bakhle Y.S.; Botting R.M.; Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998,38,97-120","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/1-4020-5688-5_1","volume":"42","author":"Rainsford K.D.","year":"2007","unstructured":"Rainsford K.D.; Anti-inflammatory drugs in the 21st century. Subcell Biochem 2007,42,3-27","journal-title":"Subcell Biochem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2S","DOI":"10.1016\/S0002-9343(97)00203-9","volume":"104","author":"Vane J.R.","year":"1998","unstructured":"Vane J.R.; Botting R.M.; Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998,104(3A),2S-8S","journal-title":"Am J Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","volume":"15","author":"Liu B.","year":"2015","unstructured":"Liu B.; Qu L.; Yan S.; Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int 2015,15,106","journal-title":"Cancer Cell Int"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.rmed.2003.09.006","volume":"98","author":"Petkova D.K.","year":"2004","unstructured":"Petkova D.K.; Clelland C.; Ronan J.; Pang L.; Coulson J.M.; Lewis S.; Knox A.J.; Overexpression of cyclooxygenase-2 in non-small cell lung cancer. Respir Med 2004,98(2),164-172","journal-title":"Respir Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3892\/ijo.26.5.1393","volume":"26","author":"Singh B.","year":"2005","unstructured":"Singh B.; Berry J.A.; Shoher A.; Ramakrishnan V.; Lucci A.; COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 2005,26(5),1393-1399","journal-title":"Int J Oncol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1073\/pnas.94.7.3336","volume":"94","author":"Tsujii M.","year":"1997","unstructured":"Tsujii M.; Kawano S.; DuBois R.N.; Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997,94(7),3336-3340","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/S0959-8049(01)00160-5","volume":"37","author":"Nakanishi Y.","year":"2001","unstructured":"Nakanishi Y.; Kamijo R.; Takizawa K.; Hatori M.; Nagumo M.; Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines. Eur J Cancer 2001,37(12),1570-1578","journal-title":"Eur J Cancer"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0145-2126(03)00183-8","volume":"28","author":"Wun T.","year":"2004","unstructured":"Wun T.; McKnight H.; Tuscano J.M.; Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res 2004,28(2),179-190","journal-title":"Leuk Res"},{"key":"ref=44","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/215158","author":"Sobolewski C.","year":"2010","unstructured":"Sobolewski C.; Cerella C.; Dicato M.; Ghibelli L.; Diederich M.; The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol 2010","journal-title":"Int J Cell Biol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1755-3768.2009.01765.x","volume":"89","author":"Wang J.","year":"2011","unstructured":"Wang J.; Wu Y.; Heegaard S.; Kolko M.; Cyclooxygenase-2 expression in the normal human eye and its expression pattern in selected eye tumours. Acta Ophthalmol 2011,89(7),681-685","journal-title":"Acta Ophthalmol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S0002-9394(99)00355-4","volume":"129","author":"Karim M.M.","year":"2000","unstructured":"Karim M.M.; Hayashi Y.; Inoue M.; Imai Y.; Ito H.; Yamamoto M.; Cox-2 expression in retinoblastoma. Am J Ophthalmol 2000,129(3),398-401","journal-title":"Am J Ophthalmol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ajo.2006.05.053","volume":"142","author":"Souza Filho J.P.","year":"2006","unstructured":"Souza Filho J.P.; Martins M.C.; Correa Z.M.; Odashiro A.N.; Antecka E.; Coutinho A.B.; Macedo C.R.; Vianna R.N.; Burnier M.N.; The expression of cyclooxygenase 2 in retinoblastoma: primary enucleated eyes and enucleation after conservative treatment. Am J Ophthalmol 2006,142(4),625-631","journal-title":"Am J Ophthalmol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/sj.eye.6701938","volume":"20","author":"de Souza Filho J.P.","year":"2006","unstructured":"de Souza Filho J.P.; Correa Z.M.; Marshall J.C.; Anteka E.; Coutinho A.B.; Martins M.C.; Burnier M.N.; The effect of a selective cyclooxygenase-2 (COX-2) inhibitor on the proliferation rate of retinoblastoma cell lines. Eye (Lond) 2006,20(5),598-601","journal-title":"Eye (Lond)"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1136\/bjo.2004.064915","volume":"89","author":"Tong C.T.","year":"2005","unstructured":"Tong C.T.; Howard S.A.; Shah H.R.; Van Quill K.R.; Lin E.T.; Grossniklaus H.E.; O\u2019Brien J.M.; Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma. Br J Ophthalmol 2005,89(9),1217-1220","journal-title":"Br J Ophthalmol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000355844","volume":"51","author":"Zheng Q.","year":"2014","unstructured":"Zheng Q.; Zhang Y.; Ren Y.; Wu Y.; Yang S.; Zhang Y.; Chen H.; Li W.; Zhu Y.; Antiproliferative and apoptotic effects of indomethacin on human retinoblastoma cell line Y79 and the involvement of \u03b2-catenin, nuclear factor-\u03baB and Akt signaling pathways. Ophthalmic Res 2014,51(2),109-115","journal-title":"Ophthalmic Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fonc.2013.00181","volume":"3","author":"Gurpinar E.","year":"2013","unstructured":"Gurpinar E.; Grizzle W.E.; Piazza G.A.; COX-Independent mechanisms of cancer chemoprevention by anti-inflammatory drugs. Front Oncol 2013,3,181","journal-title":"Front Oncol"},{"key":"ref=52","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/794930","author":"Calder\u00f3n-Monta\u00f1o J.M.","year":"2014","unstructured":"Calder\u00f3n-Monta\u00f1o J.M.; Burgos-Mor\u00f3n E.; Orta M.L.; Maldonado-Navas D.; Garc\u00eda-Dom\u00ednguez I.; L\u00f3pez-L\u00e1zaro M.; Evaluating the cancer therapeutic potential of cardiac glycosides. BioMed Res Int 2014","journal-title":"BioMed Res Int"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s10637-013-9984-1","volume":"31","author":"Slingerland M.","year":"2013","unstructured":"Slingerland M.; Cerella C.; Guchelaar H.J.; Diederich M.; Gelderblom H.; Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials. Invest New Drugs 2013,31(4),1087-1094","journal-title":"Invest New Drugs"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1124\/mi.8.1.8","volume":"8","author":"Newman R.A.","year":"2008","unstructured":"Newman R.A.; Yang P.; Pawlus A.D.; Block K.I.; Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 2008,8(1),36-49","journal-title":"Mol Interv"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/nrd2682","volume":"7","author":"Prassas I.","year":"2008","unstructured":"Prassas I.; Diamandis E.P.; Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov 2008,7(11),926-935","journal-title":"Nat Rev Drug Discov"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/j.bbamem.2007.04.012","volume":"1768","author":"Kulikov A.","year":"2007","unstructured":"Kulikov A.; Eva A.; Kirch U.; Boldyrev A.; Scheiner-Bobis G.; Ouabain activates signaling pathways associated with cell death in human neuroblastoma. Biochim Biophys Acta 2007,1768(7),1691-1702","journal-title":"Biochim Biophys Acta"},{"key":"ref=57","first-page":"109","volume":"63","author":"Winnicka K.","year":"2006","unstructured":"Winnicka K.; Bielawski K.; Bielawska A.; Cardiac glycosides in cancer research and cancer therapy. Acta Pol Pharm 2006,63(2),109-115","journal-title":"Acta Pol Pharm"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1021\/np050226l","volume":"68","author":"L\u00f3pez-L\u00e1zaro M.","year":"2005","unstructured":"L\u00f3pez-L\u00e1zaro M.; Pastor N.; Azrak S.S.; Ayuso M.J.; Austin C.A.; Cort\u00e9s F.; Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J Nat Prod 2005,68(11),1642-1645","journal-title":"J Nat Prod"},{"key":"ref=59","first-page":"167","volume":"5","author":"Newman R.A.","year":"2006","unstructured":"Newman R.A.; Yang P.; Hittelman W.N.; Lu T.; Ho D.H.; Ni D.; Chan D.; Vijjeswarapu M.; Cartwright C.; Dixon S.; Felix E.; Addington C.; Oleandrin-mediated oxidative stress in human melanoma cells. J Exp Ther Oncol 2006,5(3),167-181","journal-title":"J Exp Ther Oncol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1167\/iovs.08-3158","volume":"50","author":"Antczak C.","year":"2009","unstructured":"Antczak C.; Kloepping C.; Radu C.; Genski T.; M\u00fcller-Kuhrt L.; Siems K.; de Stanchina E.; Abramson D.H.; Djaballah H.; Revisiting old drugs as novel agents for retinoblastoma: in vitro and in vivo antitumor activity of cardenolides. Invest Ophthalmol Vis Sci 2009,50(7),3065-3073","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/13816810.2010.544530","volume":"32","author":"Patel M.","year":"2011","unstructured":"Patel M.; Paulus Y.M.; Gobin Y.P.; Djaballah H.; Marr B.; Dunkel I.J.; Brodie S.; Antczak C.; Folberg R.; Abramson D.H.; Intra-arterial and oral digoxin therapy for retinoblastoma. Ophthalmic Genet 2011,32(3),147-150","journal-title":"Ophthalmic Genet"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1167\/iovs.14-16239","volume":"56","author":"Winter U.","year":"2015","unstructured":"Winter U.; Buitrago E.; Mena H.A.; Del Sole M.J.; Laurent V.; Negrotto S.; Francis J.; Arana E.; Sgroi M.; Croxatto J.O.; Djaballah H.; Chantada G.L.; Abramson D.; Schaiquevich P.; Pharmacokinetics, safety, and efficacy of intravitreal Digoxin in preclinical models for retinoblastoma. Invest Ophthalmol Vis Sci 2015,56(8),4382-4393","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/CAD.0000000000000236","volume":"26","author":"Zhang H.","year":"2015","unstructured":"Zhang H.; Jing X.; Wu X.; Hu J.; Zhang X.; Wang X.; Su P.; Li W.; Zhou G.; Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes. Anticancer Drugs 2015,26(7),706-715","journal-title":"Anticancer Drugs"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00411-016-0679-9","volume":"56","author":"An Z.","year":"2017","unstructured":"An Z.; Yu J.R.; Park W.Y.; Rosiglitazone enhances radiosensitivity by inhibiting repair of DNA damage in cervical cancer cells. Radiat Environ Biophys 2017,56(1),89-98","journal-title":"Radiat Environ Biophys"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.biopha.2016.06.047","volume":"83","author":"Wang H.Y.","year":"2016","unstructured":"Wang H.Y.; Zhang Y.; Zhou Y.; Lu Y.Y.; Wang W.F.; Xin M.; Guo X.L.; Rosiglitazone elevates sensitization of drug-resistant oral epidermoid carcinoma cells to vincristine by G2\/M-phase arrest, independent of PPAR-\u03b3 pathway. Biomed Pharmacother 2016,83,349-361","journal-title":"Biomed Pharmacother"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.3892\/ol.2015.3554","volume":"10","author":"Bo Q.F.","year":"2015","unstructured":"Bo Q.F.; Sun X.M.; Liu J.; Sui X.M.; Li G.X.; Antitumor action of the peroxisome proliferator-activated receptor-\u03b3 agonist rosiglitazone in hepatocellular carcinoma. Oncol Lett 2015,10(4),1979-1984","journal-title":"Oncol Lett"},{"key":"ref=67","first-page":"12549","volume":"8","author":"Cao X.","year":"2015","unstructured":"Cao X.; He L.; Li Y.; Effects of PPAR\u03b3 agonistrosiglitazone on human retinoblastoma cell in vitro and in vivo. Int J Clin Exp Pathol 2015,8(10),12549-12556","journal-title":"Int J Clin Exp Pathol"},{"key":"ref=68","first-page":"13","volume":"121","author":"Smith U.","year":"2001","unstructured":"Smith U.; Pioglitazone: mechanism of action. Int J Clin Pract Suppl 2001,121,13-18","journal-title":"Int J Clin Pract Suppl"},{"key":"ref=69","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/704165","author":"Elrod H.A.","year":"2008","unstructured":"Elrod H.A.; Sun S.Y.; PPARgamma and Apoptosis in Cancer. PPAR Res 2008","journal-title":"PPAR Res"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"532","DOI":"10.2174\/156652407781695765","volume":"7","author":"Krishnan A.","year":"2007","unstructured":"Krishnan A.; Nair S.A.; Pillai M.R.; Biology of PPAR gamma in cancer: a critical review on existing lacunae. Curr Mol Med 2007,7(6),532-540","journal-title":"Curr Mol Med"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3109\/10799893.2016.1171341","volume":"37","author":"Wang F.","year":"2017","unstructured":"Wang F.; Liu Y.; Bi Z.; Pioglitazone inhibits growth of human retinoblastoma cells via regulation of NF-\u03baB inflammation signals. J Recept Signal Transduct Res 2017,37(1),94-99","journal-title":"J Recept Signal Transduct Res"},{"key":"ref=72","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3645","volume":"344","author":"Azoulay L.","year":"2012","unstructured":"Azoulay L.; Yin H.; Filion K.B.; Assayag J.; Majdan A.; Pollak M.N.; Suissa S.; The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012,344","journal-title":"BMJ"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"916","DOI":"10.2337\/dc10-1068","volume":"34","author":"Lewis J.D.","year":"2011","unstructured":"Lewis J.D.; Ferrara A.; Peng T.; Hedderson M.; Bilker W.B.; Quesenberry C.P.; Vaughn D.J.; Nessel L.; Selby J.; Strom B.L.; Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011,34(4),916-922","journal-title":"Diabetes Care"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.molmed.2007.08.001","volume":"13","author":"Chiang G.G.","year":"2007","unstructured":"Chiang G.G.; Abraham R.T.; Targeting the mTOR signaling network in cancer. Trends Mol Med 2007,13(10),433-442","journal-title":"Trends Mol Med"},{"key":"ref=75","first-page":"683","volume":"15","author":"Zi F.","year":"2018","unstructured":"Zi F.; Zi H.; Li Y.; He J.; Shi Q.; Cai Z.; Metformin and cancer: An existing drug for cancer prevention and therapy. Oncol Lett 2018,15(1),683-690","journal-title":"Oncol Lett"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.urolonc.2011.01.003","volume":"31","author":"Liu J.","year":"2013","unstructured":"Liu J.; Li M.; Song B.; Jia C.; Zhang L.; Bai X.; Hu W.; Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol 2013,31(2),264-270","journal-title":"Urol Oncol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/j.1872-034X.2012.01007.x","volume":"42","author":"Qu Z.","year":"2012","unstructured":"Qu Z.; Zhang Y.; Liao M.; Chen Y.; Zhao J.; Pan Y.; In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma. Hepatol Res 2012,42(9),922-933","journal-title":"Hepatol Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ygyno.2017.07.120","volume":"147","author":"Meireles C.G.","year":"2017","unstructured":"Meireles C.G.; Pereira S.A.; Valadares L.P.; R\u00eago D.F.; Simeoni L.A.; Guerra E.N.S.; Lofrano-Porto A.; Effects of metformin on endometrial cancer: Systematic review and meta-analysis. Gynecol Oncol 2017,147(1),167-180","journal-title":"Gynecol Oncol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1158\/1078-0432.CCR-09-1805","volume":"16","author":"Gonzalez-Angulo A.M.","year":"2010","unstructured":"Gonzalez-Angulo A.M.; Meric-Bernstam F.; Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 2010,16(6),1695-1700","journal-title":"Clin Cancer Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3727\/096504011X13021877989838","volume":"19","author":"Malki A.","year":"2011","unstructured":"Malki A.; Youssef A.; Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol Res 2011,19(6),275-285","journal-title":"Oncol Res"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.3892\/ijo.2014.2650","volume":"45","author":"Brodowska K.","year":"2014","unstructured":"Brodowska K.; Theodoropoulou S.; Meyer Zu H\u00f6rste M.; Paschalis E.I.; Takeuchi K.; Scott G.; Ramsey D.J.; Kiernan E.; Hoang M.; Cichy J.; Miller J.W.; Gragoudas E.S.; Vavvas D.G.; Effects of metformin on retinoblastoma growth in vitro and in vivo. Int J Oncol 2014,45(6),2311-2324","journal-title":"Int J Oncol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"C539","DOI":"10.1152\/ajpcell.00047.2010","volume":"299","author":"Griffin M.O.","year":"2010","unstructured":"Griffin M.O.; Fricovsky E.; Ceballos G.; Villarreal F.; Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010,299(3),C539-C548","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1600-051X.2004.00558.x","volume":"31","author":"Preshaw P.M.","year":"2004","unstructured":"Preshaw P.M.; Hefti A.F.; Jepsen S.; Etienne D.; Walker C.; Bradshaw M.H.; Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review. J Clin Periodontol 2004,31(9),697-707","journal-title":"J Clin Periodontol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.phrs.2010.12.003","volume":"63","author":"Caton J.","year":"2011","unstructured":"Caton J.; Ryan M.E.; Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline (SDD). Pharmacol Res 2011,63(2),114-120","journal-title":"Pharmacol Res"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bbrc.2016.02.120","volume":"472","author":"Li J.","year":"2016","unstructured":"Li J.; Huang Y.; Gao Y.; Wu H.; Dong W.; Liu L.; Antibiotic drug rifabutin is effective against lung cancer cells by targeting the eIF4E-\u03b2-catenin axis. Biochem Biophys Res Commun 2016,472(2),299-305","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1139\/cjpp-2015-0481","volume":"94","author":"Zhao Y.","year":"2016","unstructured":"Zhao Y.; Wang X.; Li L.; Li C.; Doxycycline inhibits proliferation and induces apoptosis of both human papillomavirus positive and negative cervical cancer cell lines. Can J Physiol Pharmacol 2016,94(5),526-533","journal-title":"Can J Physiol Pharmacol"},{"key":"ref=87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134201","volume":"10","author":"Yang B.","year":"2015","unstructured":"Yang B.; Lu Y.; Zhang A.; Zhou A.; Zhang L.; Zhang L.; Gao L.; Zang Y.; Tang X.; Sun L.; Correction: Doxycycline induces apoptosis and inhibits proliferation and invasion of human cervical carcinoma stem cells. PLoS One 2015,10(7)","journal-title":"PLoS One"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"75954","DOI":"10.18632\/oncotarget.12488","volume":"7","author":"Alexander-Savino C.V.","year":"2016","unstructured":"Alexander-Savino C.V.; Hayden M.S.; Richardson C.; Zhao J.; Poligone B.; Doxycycline is an NF-\u03baB inhibitor that induces apoptotic cell death in malignant T-cells. Oncotarget 2016,7(46),75954-75967","journal-title":"Oncotarget"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.18632\/oncotarget.6419","volume":"7","author":"Hu H.","year":"2016","unstructured":"Hu H.; Dong Z.; Tan P.; Zhang Y.; Liu L.; Yang L.; Liu Y.; Cui H.; Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1\/Waf1-dependent manner. Oncotarget 2016,7(3),3171-3185","journal-title":"Oncotarget"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.bbrc.2016.02.072","volume":"471","author":"Yu M.","year":"2016","unstructured":"Yu M.; Li R.; Zhang J.; Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer. Biochem Biophys Res Commun 2016,471(4),639-645","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3332\/ecancer.2015.513","volume":"9","author":"Van Nuffel A.M.","year":"2015","unstructured":"Van Nuffel A.M.; Sukhatme V.; Pantziarka P.; Meheus L.; Sukhatme V.P.; Bouche G.; Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent. Ecancermedicalscience 2015,9,513","journal-title":"Ecancermedicalscience"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.exer.2013.10.009","volume":"118","author":"Barot M.","year":"2014","unstructured":"Barot M.; Gokulgandhi M.R.; Pal D.; Mitra A.K.; In vitro moxifloxacin drug interaction with chemotherapeutics: implications for retinoblastoma management. Exp Eye Res 2014,118,61-71","journal-title":"Exp Eye Res"},{"key":"ref=93","first-page":"5182","volume":"8","author":"Wang Y.D.","year":"2015","unstructured":"Wang Y.D.; Su Y.J.; Li J.Y.; Yao X.C.; Liang G.J.; Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1. Int J Clin Exp Pathol 2015,8(5),5182-5188","journal-title":"Int J Clin Exp Pathol"},{"key":"ref=94","first-page":"10723","volume":"8","author":"Wang Y.D.","year":"2015","unstructured":"Wang Y.D.; Su Y.J.; Li J.Y.; Yao X.C.; Liang G.J.; Rapamycin, an mTOR inhibitor, induced apoptosis via independent mitochondrial and death receptor pathway in retinoblastoma Y79 cell. Int J Clin Exp Med 2015,8(7),10723-10730","journal-title":"Int J Clin Exp Med"},{"key":"ref=95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031004","volume":"7","author":"Kim J.","year":"2012","unstructured":"Kim J.; Yip M.L.; Shen X.; Li H.; Hsin L.Y.; Labarge S.; Heinrich E.L.; Lee W.; Lu J.; Vaidehi N.; Identification of an-ti-malarial compounds as novel antagonists to chemokine re-ceptor CXCR4 in pancreatic cancer cells. PLoS One 2012,7(2)","journal-title":"PLoS One"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/cas.13540","volume":"109","author":"Xu X.","year":"2018","unstructured":"Xu X.; Wang J.; Han K.; Li S.; Xu F.; Yang Y.; Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in colorectal cancer cells. Cancer Sci 2018,109(4),1220-1229","journal-title":"Cancer Sci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.3892\/ol.2013.1259","volume":"5","author":"Yan K.H.","year":"2013","unstructured":"Yan K.H.; Lin Y.W.; Hsiao C.H.; Wen Y.C.; Lin K.H.; Liu C.C.; Hsieh M.C.; Yao C.J.; Yan M.D.; Lai G.M.; Chuang S.E.; Lee L.M.; Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo. Oncol Lett 2013,5(5),1567-1571","journal-title":"Oncol Lett"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.bbrc.2016.01.046","volume":"470","author":"Liu Y.","year":"2016","unstructured":"Liu Y.; Chen S.; Xue R.; Zhao J.; Di M.; Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K\/Akt\/mTOR signaling pathway. Biochem Biophys Res Commun 2016,470(2),350-355","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1139\/cjpp-2016-0124","volume":"95","author":"Li H.","year":"2017","unstructured":"Li H.; Jiao S.; Li X.; Banu H.; Hamal S.; Wang X.; Therapeutic effects of antibiotic drug mefloquine against cervical cancer through impairing mitochondrial function and inhibiting mTOR pathway. Can J Physiol Pharmacol 2017,95(1),43-50","journal-title":"Can J Physiol Pharmacol"},{"key":"ref=100","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122603","volume":"18","author":"Harada M.","year":"2017","unstructured":"Harada M.; Morimoto K.; Kondo T.; Hiramatsu R.; Okina Y.; Muko R.; Matsuda I.; Kataoka T.; Quinacrine Inhibits ICAM-1 Transcription by Blocking DNA Binding of the NF-\u03baB Subunit p65 and Sensitizes Human Lung Adenocarcinoma A549 Cells to TNF-\u03b1 and the Fas Ligand. Int J Mol Sci 2017,18(12)","journal-title":"Int J Mol Sci"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"36354","DOI":"10.18632\/oncotarget.5632","volume":"6","author":"Khurana A.","year":"2015","unstructured":"Khurana A.; Roy D.; Kalogera E.; Mondal S.; Wen X.; He X.; Dowdy S.; Shridhar V.; Quinacrine promotes autophagic cell death and chemosensitivity in ovarian cancer and attenuates tumor growth. Oncotarget 2015,6(34),36354-36369","journal-title":"Oncotarget"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.3892\/or.2013.2574","volume":"30","author":"Zhao F.","year":"2013","unstructured":"Zhao F.; Wang H.; Kunda P.; Chen X.; Liu Q.L.; Liu T.; Artesunate exerts specific cytotoxicity in retinoblastoma cells via CD71. Oncol Rep 2013,30(3),1473-1482","journal-title":"Oncol Rep"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.bbrc.2018.06.049","volume":"504","author":"Ke F.","year":"2018","unstructured":"Ke F.; Yu J.; Chen W.; Si X.; Li X.; Yang F.; Liao Y.; Zuo Z.; The anti-malarial atovaquone selectively increases chemosensitivity in retinoblastoma via mitochondrial dysfunction-dependent oxidative damage and Akt\/AMPK\/mTOR inhibition. Biochem Biophys Res Commun 2018,504(2),374-379","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1179\/joc.1996.8.4.295","volume":"8","author":"Timcheva C.V.","year":"1996","unstructured":"Timcheva C.V.; Todorov D.K.; Does verapamil help overcome multidrug resistance in tumor cell lines and cancer patients? J Chemother 1996,8(4),295-299","journal-title":"J Chemother"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.7150\/thno.17451","volume":"7","author":"Zhou J.","year":"2017","unstructured":"Zhou J.; Jin B.; Jin Y.; Liu Y.; Pan J.; The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo. Theranostics 2017,7(6),1447-1462","journal-title":"Theranostics"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3332\/ecancer.2014.485","volume":"8","author":"Pantziarka P.","year":"2014","unstructured":"Pantziarka P.; Bouche G.; Meheus L.; Sukhatme V.; Sukhatme V.P.; Vikas P.; The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience 2014,8,442","journal-title":"Ecancermedicalscience"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/S0161-6420(99)90406-2","volume":"106","author":"Abramson D.H.","year":"1999","unstructured":"Abramson D.H.; Frank C.M.; Dunkel I.J.; A phase I\/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 1999,106(10),1947-1950","journal-title":"Ophthalmology"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ajo.2006.02.044","volume":"142","author":"Schmack I.","year":"2006","unstructured":"Schmack I.; Hubbard G.B.; Kang S.J.; Aaberg T.M.; Grossniklaus H.E.; Ischemic necrosis and atrophy of the op-tic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol 2006,142(2),310-315","journal-title":"Am J Ophthalmol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3892\/or.2013.2279","volume":"29","author":"Astolfi L.","year":"2013","unstructured":"Astolfi L.; Ghiselli S.; Guaran V.; Chicca M.; Simoni E.; Olivetto E.; Lelli G.; Martini A.; Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation. Oncol Rep 2013,29(4),1285-1292","journal-title":"Oncol Rep"},{"key":"ref=110","first-page":"169","volume":"4","author":"Shahsavari M.","year":"2009","unstructured":"Shahsavari M.; Mashayekhi A.; Pharmacotherapy for retinoblastoma. J Ophthalmic Vis Res 2009,4(3),169-173","journal-title":"J Ophthalmic Vis Res"},{"key":"ref=111","first-page":"370","author":"Perry M.C.","year":"2008","unstructured":"Perry M.C.;  Principles of cancer therapyCecil textbook of medicine; 2008,370-386","journal-title":"Principles of cancer therapyCecil textbook of medicine;"},{"key":"ref=112","first-page":"514","author":"Sausville E.A.","year":"2008","unstructured":"Sausville E.A.; Longo D.L.;   2008,514-533","journal-title":""},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/pbc.20380","volume":"45","author":"Le Deley M.C.","year":"2005","unstructured":"Le Deley M.C.; Vassal G.; Ta\u00efbi A.; Shamsaldin A.; Leblanc T.; Hartmann O.; High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatr Blood Cancer 2005,45(1),25-31","journal-title":"Pediatr Blood Cancer"},{"key":"ref=114","first-page":"35","volume":"19","author":"Smit E.F.","year":"1992","unstructured":"Smit E.F.; Ousterhuis B.E.; Berendsen H.H.; Sleijfer D.T.; Postmus P.E.; Phase I study of oral teniposide (VM-26). Semin Oncol 1992,19(2)(Suppl. 6),35-39","journal-title":"Semin Oncol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1001\/archophthalmol.2011.130","volume":"129","author":"Mallipatna A.C.","year":"2011","unstructured":"Mallipatna A.C.; Dimaras H.; Chan H.S.L.; H\u00e9on E.; Gallie B.L.; Periocular topotecan for intraocular retinoblastoma. Arch Ophthalmol 2011,129(6),738-745","journal-title":"Arch Ophthalmol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1136\/bjophthalmol-2013-303885","volume":"98","author":"Smith S.J.","year":"2014","unstructured":"Smith S.J.; Smith B.D.; Mohney B.G.; Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol 2014,98(3),292-297","journal-title":"Br J Ophthalmol"},{"key":"ref=117","first-page":"445","volume":"11","author":"Said A.M.A.","year":"2018","unstructured":"Said A.M.A.; Aly M.G.; Rashed H.O.; Rady A.M.; Safety and efficacy of posterior sub-Tenon\u2019s carboplatin injection versus intravitreal melphalan therapy in the management of retinoblastoma with secondary vitreous seeds. Int J Ophthalmol 2018,11(3),445-455","journal-title":"Int J Ophthalmol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4103\/0301-4738.154390","volume":"63","author":"Manjandavida F.P.","year":"2015","unstructured":"Manjandavida F.P.; Shields C.L.; The role of intravitreal chemotherapy for retinoblastoma. Indian J Ophthalmol 2015,63(2),141-145","journal-title":"Indian J Ophthalmol"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.ophtha.2011.02.005","volume":"118","author":"Kivel\u00e4 T.","year":"2011","unstructured":"Kivel\u00e4 T.; Eskelin S.; Paloheimo M.; Intravitreal methotrex-ate for retinoblastoma. Ophthalmology 2011,118(8),1689","journal-title":"Ophthalmology"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/169178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T10:08:32Z","timestamp":1571738912000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/169178\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,19]]},"references-count":119,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2019,9,19]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026619666190119152706","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,19]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}